Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells

Nigel P. Mongan and Lorraine J. Gudas
Nigel P. Mongan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorraine J. Gudas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-04-0079 Published March 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, cells were treated twice over a 96-h period with ethanol (lane 1), RA (1 μmol/L; lane 2), VPA (250 μmol/L; lane 3), RA + VPA (lane 4), Aza-dC (2 μmol/L; lane 5), RA + Aza-dC (lane 6), and RA + Aza-dC + VPA (lane 7) and RT-PCR was done as described in Materials and Methods. PCR products were analyzed by electrophoreses on 1.5% TAE-agarose gel and stained with ethidium bromide. B and C, ChIP assays using an antibody to acetylated histone H3 were used to assess the ability of 1 μmol/L RA (B, lane 1) or 2 μmol/L Aza-dC (B, lane 2) in combination with differing VPA concentrations (C, lanes 1-5) to restore histone H3 acetylation to the RARβ2 P2 promoter. Cells were treated twice over a 96-h period with RA and Aza-dC in combination with 5 mmol/L VPA (C, lane 1), 3 mmol/L VPA (C, lane 2), 1 mmol/L VPA (C, lane 3), 500 μmol/L VPA (C, lane 4), 250 μmol/L VPA (C, lane 5), RA + Aza-dC (C, lane 6), and vehicle control (C, lane 7). Immediately before the ChIP assay, RA (1 μmol/L) and β-estradiol (100 nmol/L) were added to the cells for 30 minutes before formaldehyde cross-linking and histone H3 acetylation assessed at the RARβ2-RARE. The promoter regions of PS2 and GAPDH act as internal positive controls. Thirty-two (B) and 33 (C) cycles of PCR were used in the ChIP experiments. PCRs were analyzed by electrophoresis on a 2% TAE-agarose gel and repeated yielding similar results. βE2, β-estradiol; C, Aza-dC; IP, immunoprecipitation with anti–histone H3 antibody; R, RA; V, VPA.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    RT-PCR was used to detect expression of RARα (314 bp), RARβ (256 bp), and RARγ (394 bp) in MCF-7 (A), MDA-MB-231 (B), MDA-MB-453 (C), SK-BR3 (D), and HS578T (E) breast cancer cells. Amplification of β-actin (379 bp) was used to confirm cDNA integrity. Cells were treated twice over a 96-h period with ethanol (lane 1), RA (1 μmol/L; lane 2), VPA (250 μmol/L; lane 3), RA + VPA (lane 4), Aza-dC (2 μmol/L; lane 5), RA + Aza-dC (lane 6), and RA + Aza-dC + VPA (lane 7) and RT-PCR was done as described in Materials and Methods. A nonspecific amplification product was observed in control and VPA-treated MDA-MB-231 cells (B) and control MDA-MB-453 cells (C). The identity of the PCR product of each primer pair was confirmed by automated DNA sequencing. PCR products were analyzed by electrophoreses on 1.5% TAE-agarose gel and stained with ethidium bromide.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Real-time PCR (A-D) was done as described in Materials and Methods. Cells were treated twice over a 96-h period with RA (1 μmol/L), VPA (250 μmol/L), RA + VPA, Aza-dC (2 μmol/L), RA + Aza-dC, and RA + Aza-dC + VPA. The expression of RARβ2 was measured relative to cellular β-actin levels and quantified relative to calibrator sample (asterisks). Real-time PCR analysis was done in triplicate for each sample. Columns, mean; bars, SD. No signal indicates that RARβ2 was not detected under the conditions used. R, RA (1 μmol/L); V, VPA (250 μmol/L); C, Aza-dC (2 μmol/L); Con, control.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Proliferation of MCF-7 (A-C) and MDA-MB-231 (D-F) breast cancer cells was monitored in cells treated twice with combinations of VPA (250 μmol/L), RA (1 μmol/L), and Aza-dC (2 μmol/L) during the 96-h growth experiment. Growth inhibition expressed as percentage of untreated control MCF-7 (C) and MDA-MB-231 (F) cells is displayed to permit comparison between experiments done on different occasions. Growth assays were done on a minimum of four occasions. Points, mean; bars, SE.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    RT-PCR was used to detect expression of RARβ in MCF-7 (A), MDA-MB-231 (C), MDA-MB-453 (E), and SK-BR3 (G) breast cancer cells. Amplification of β-actin was used to confirm cDNA integrity. Cells were treated twice over a 96-h period with ethanol, RA (1 μmol/L), and Aza-dC (2 μmol/L) with decreasing VPA concentrations (lane 1); RA + Aza-dC + VPA (250 μmol/L; lane 2); RA + Aza-dC + VPA (100 μmol/L; lane 3); RA + Aza-dC + VPA (50 μmol/L; lane 4); and RA + Aza-dC (lane 5). RT-PCR was done as described in Materials and Methods. PCR products were analyzed by electrophoreses on 1.5% TAE-agarose gels and stained with ethidium bromide. Proliferation of MCF-7 (B), MDA-MB-231 (D), MDA-MB-453 (F), and SK-BR3 (H) breast cancer cells was monitored in cells treated twice with combinations of RA (1 μmol/L) with Aza-dC (2 μmol/L) and varying VPA concentrations as indicated during the 96-h growth experiment. Cell number was measured after 96-h growth. Growth assays were done in quadruplicate. Columns, mean; bars, SE.

Tables

  • Figures
  • Table 1.

    Sequences of primer pairs used to assess mRNA expression using RT-PCR

    GeneSense primer (5′-3′)Antisense primer (5′-3′)Product (bp)
    RARαGTCTGTCAGGACAAGTCCTCAGGGCTTTGCGCACCTTCTCAATGAG314
    RARβ2GACTGTATGGATGTTCTGTCAGATTTGTCCTGGCAGACGAAGC255
    RARγAATGACAAGTCCTCTGGCTACCACCAGATCCAGCTGCACGCGGTGGTC394
    β-actinGCTCGTCGTCGACAACGGCTCGTACATGGCTGGGGTGTTGAAGG379
    • NOTE: The identity the product of each primer pair was confirmed by automated DNA sequencing.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 4 (3)
March 2005
Volume 4, Issue 3
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells
Nigel P. Mongan and Lorraine J. Gudas
Mol Cancer Ther March 1 2005 (4) (3) 477-486; DOI: 10.1158/1535-7163.MCT-04-0079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells
Nigel P. Mongan and Lorraine J. Gudas
Mol Cancer Ther March 1 2005 (4) (3) 477-486; DOI: 10.1158/1535-7163.MCT-04-0079
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement